Ant Nano presentation to CONNECT North East Conference 09


Published on

Ant Nano presentation to CONNECT North East Conference 09

Published in: Business, Technology
1 Like
  • Be the first to comment

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Ant Nano presentation to CONNECT North East Conference 09

  1. 1. <ul><li>AntNano Plc is a biological and chemical air quality analysis company specialising in the detection of hazardous materials using proprietary nanotechnology solutions </li></ul><ul><li>Dr Allan Syms </li></ul><ul><li>Chief Executive Officer April 2009 </li></ul>STRICTLY CONFIDENTIAL
  2. 2. STRICTLY CONFIDENTIAL This presentation has been issued in connection with a proposed placing (the “Placing”) of new ordinary shares in AntNano plc (the “Company”). The content of this promotion has not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000. Reliance on this promotion for the purpose of engaging in any investment activity may expose an individual to a significant risk of losing all of the property or other assets invested. The information in this presentation is subject to updating, completion, revision, further verification and amendment without notice. No assurance is given by the Company that any ordinary shares of the Company will be sold in the Placing. This presentation does not constitute, or form part of, any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for, any shares in the Company, nor shall it (or any part of it) or the fact of its distribution, form the basis of, or be relied on in connection with, or act as an inducement to enter into any contract or commitment therefore. No reliance may be placed for any purpose whatsoever on the information or opinions contained in this presentation or any other document or oral statement, or on the completeness, accuracy or fairness of such information and/or opinions therein. No representation or warranty, express or implied, is made or given by or on behalf of the Company, any of their respective directors, or any other person as to the accuracy or completeness or fairness of the information or opinions contained in this presentation and no responsibility or liability is accepted by any of them for such information or opinions or for any errors, omissions, misstatements, negligent or otherwise, or for any communication written or otherwise, contained or referred to in this presentation. DISCLAIMER
  3. 3. STRICTLY CONFIDENTIAL Accordingly, neither the Company nor any of their respective directors, officers, employees, advisers, associated persons or subsidiary undertakings shall be liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon the statement or as a result of any admission in, or any document supplied with, this presentation or by any future communications in connection with such documents and any such liabilities are expressly disclaimed. Prospective investors interested in investing in the Company are recommended to seek their own independent financial advice from a person authorised for the purposes of the Financial Services and Markets Act 2000. This presentation and its contents are confidential and should not be distributed, published or reproduced in whole or in part or disclosed by recipients to any other person. This presentation is not for distribution outside the United Kingdom and, in particular, should not be distributed to persons with addresses in Canada, Australia, Japan, Republic of Ireland, Republic of South Africa, or to persons with addresses in the United States of America, its territories or possession or to any citizen thereof or to any corporation, partnership or other entity created or organized under the laws thereof. Any such distribution could result in the violation of Canadian, Australian, Japanese, Irish, South African or United States of America law. The information in this presentation is confidential and must not be copied, reproduced or distributed to others at any time except for the purposes of analysis by certain employees and advisers of the recipient who have agreed to be bound by the restrictions contained herein. DISCLAIMER (cont.)
  4. 4. STRICTLY CONFIDENTIAL <ul><li>Originally created for Unilever and P&G to find better solutions for to detect airborne agents hazardous to human health: </li></ul><ul><ul><li>Address needs driven by legislation for controlling exposure </li></ul></ul><ul><ul><li>Provide greater sensitivity in detecting hazardous materials (chemicals, biological agents, explosives) </li></ul></ul><ul><ul><li>Real time analysis in the field or at the risk site </li></ul></ul>Market Pull; Not Tech Push
  5. 5. STRICTLY CONFIDENTIAL The Economic Argument Time Hrs Amortised Cost/test £ Existing Galley Sampler >150 64 New AntNano Dip Strips 4 30 AntNano Real Time Analyser 0.1 1.5
  6. 6. Real Time Air Analyser <ul><li>Airborne enzyme is captured by a cyclone </li></ul><ul><li>Fluid passing through cyclone which transfers enzyme into liquid phase </li></ul><ul><li>Enzyme solution passes through bioreactor </li></ul><ul><li>Bioreactor substrate material is digested and fluorescent marker is released </li></ul><ul><li>Fluorescence is measured and is proportional to enzyme concentration </li></ul>STRICTLY CONFIDENTIAL Cyclone Bioreactor Fluorimeter Fluid In Air In Air Out Waste
  7. 7. STRICTLY CONFIDENTIAL High Volume Air Sampling Real Time Measurement Monitoring of Airborne Enzymes Current Product Range
  8. 8. STRICTLY CONFIDENTIAL Route to Market   <ul><li>Group is a world leader in static airborne industrial enzyme monitoring (via Newton) </li></ul><ul><li>600 installations worldwide that presents immediate access for real-time analysers, bioreactors, and dip strips </li></ul><ul><li>Currently established in the detergent industry – horizontal marketing segments such as food and beverage, tannery, paper and pulp, animal feed. </li></ul><ul><li>Corporate partnerships and licensing – by combining new sensor technologies with existing air monitoring nanotechnologies for security and biomedical applications </li></ul>
  9. 9. STRICTLY CONFIDENTIAL Customers   <ul><li>Initially concentrating sales and marketing (Consortium members) </li></ul><ul><li>Unilever Limited </li></ul><ul><li>The Procter & Gamble Company </li></ul><ul><li>Johnson Diversey Limited </li></ul><ul><li>Novozymes A/S </li></ul>Industrial (Enzyme Detection) Oestrogen Steroid Detection Dioxin Detection Infectious Disease Detection Counter Terrorism <ul><li>Enzyme Manufacturers </li></ul><ul><li>Manufacturers of Detergent Products </li></ul><ul><li>Bakeries </li></ul><ul><li>Pharmaceutical manufacturers </li></ul><ul><li>Water authorities </li></ul><ul><li>large scale manufacturing companies (e.g. cement factories) </li></ul><ul><li>institutions with chimney stacks </li></ul><ul><li>dioxin specific commercial laboratories </li></ul><ul><li>governmental organizations </li></ul><ul><li>environmental consultants. </li></ul><ul><li>major global players </li></ul><ul><li>hospitals and healthcare institutions for monitoring infectious diseases </li></ul><ul><li>animal husbandry and farms </li></ul><ul><li>military for rapid detection of biological agents. </li></ul><ul><li>global partners </li></ul><ul><li>Immigration Authority for explosives; and </li></ul><ul><li>the military for detecting biological agents and improvised explosive devices. </li></ul>
  10. 10. STRICTLY CONFIDENTIAL Sustainable Advantages <ul><li>Products’ capabilities and advantages </li></ul><ul><li>Inexpensive </li></ul><ul><li>Rapid (a few minutes versus > a few days for lab-based analysis) </li></ul><ul><li>Specific </li></ul><ul><li>Sensitive </li></ul><ul><li>Suitable for non-invasive testing </li></ul><ul><li>Easy to use </li></ul><ul><li>Company core competences and advantages </li></ul><ul><li>Core team of experienced managers, research scientists and engineers in the application of nanotechnologies is a variety of markets </li></ul><ul><li>Strong suite of patents and expected commercialisable new discoveries and novel inventions </li></ul><ul><li>Providing real time analysis of airborne chemical and biological agents </li></ul>
  11. 11. <ul><li>Heightened risk of chemical, explosive and biomedical threats </li></ul><ul><li>Detection vital at airports, stadia, diplomatic conferences, other large public events and for protection of military personnel. </li></ul><ul><li>Current technology involves differing detection systems </li></ul><ul><ul><li>Imaging: i.e. X-Ray of Terahertz. </li></ul></ul><ul><ul><li>Chemical: Sensing i.e. IMS, Canine Olfaction </li></ul></ul><ul><ul><li>Biomedical diagnostics e.g. PCR </li></ul></ul><ul><li>Technology limited either by: </li></ul><ul><ul><li>Access </li></ul></ul><ul><ul><li>Sensitivity </li></ul></ul><ul><ul><li>Speed </li></ul></ul>Security Applications
  12. 12. ANT Explosive Approach
  13. 13. <ul><li>Proven track record: </li></ul><ul><ul><li>Developed start-up companies to become self sustaining and quoted businesses, in bio and nanotechnology worth >£500m </li></ul></ul><ul><ul><li>Directors have leveraged personal networks to develop business internationally </li></ul></ul><ul><ul><li>Have personally guaranteed bank loans and leases for £200K </li></ul></ul><ul><ul><li>Are a team with a blend of Commercial , Scientific and Financial skills </li></ul></ul>STRICTLY CONFIDENTIAL Management
  14. 14. <ul><li>Mr Joe Arend: Chairman </li></ul><ul><li>Founder of AntNano and ex senior director of Proctor and Gamble, Rhone Poulenc. Founding member of successful start-ups </li></ul><ul><li>Dr Allan Syms: Chief Executive </li></ul><ul><li>Ex CEO of nanotechnology and sensor start-ups resulting in public listing </li></ul><ul><li>Prof Fred Rowell: Chief Scientific Officer </li></ul><ul><li>Founder of AntNano and renowned expert in nanotechnology and enzyme measurement </li></ul><ul><li>Mr Alec Craig: Non-Executive Director </li></ul><ul><li>Senior Partner of Halliwells LLP, Board member of VCT with key corporate governance skills </li></ul><ul><li>Mr John Haworth: Non-Executive Director </li></ul><ul><li>MD of Newton Instrument Group </li></ul>STRICTLY CONFIDENTIAL Management
  15. 15. STRICTLY CONFIDENTIAL Financial Summary
  16. 16. STRICTLY CONFIDENTIAL Summary <ul><li>Formed in 2002 with investment of £254,000 from blue-chip consortium – Unilever, Proctor & Gamble, Novozymes and Genencor </li></ul><ul><li>Subsequent investment in technology of ~£3m from shareholders, asset financing and grants </li></ul><ul><ul><li>2007: Quoted on Plus Markets with current mkt cap ~ £6m </li></ul></ul><ul><li>2007: £900K strategic alliance with NTU Singapore </li></ul><ul><li>2008: Acquired Newton Air Sampler Business </li></ul><ul><li>2008: Exclusive license to ultrasensitive microelectrode technology with option to acquire </li></ul><ul><li>2008: EDB Singapore RISC Grant ~£4.5 million </li></ul><ul><li>2008: POC grant NTU £90K infectious disease </li></ul><ul><li>2008: POC SPRING grant £115K new air sensors </li></ul><ul><li>2009: Products to market and seeking working capital </li></ul>
  17. 17. STRICTLY CONFIDENTIAL <ul><li>Now seeking up to £1.0 m to fund: </li></ul><ul><li>Sales and marketing expansion </li></ul><ul><li>Bridge financial gap between suppliers and customers (working capital) </li></ul><ul><li>Maintain IP protection </li></ul><ul><li>Microarray Ltd strategic acquisition </li></ul>Investment Opportunity